News | October 06, 2009

Direct Flow Medical Presents 12-Month Data on Percutaneous Aortic Valve System

October 6, 2009 – Direct Flow Medical Inc. released its One-year data from the initial clinical trial for its transcatheter prosthetic aortic valve during the recent Transcatheter Cardiovascular Therapeutics (TCT) 2009 meeting .

Professor Joachim Schofer from Hamburg, Germany presented the prospective, nonrandomized data from the European Feasibility and Safety Trial. A total of 31 patients were enrolled at two centers in this first in human clinical trial. The one-year risk adjusted survival rate in this study was 72 percent, which is significantly better than the predicted survival of this patient population if they were treated by conventional surgery or medical management. The survival rate is comparable to survival rates reported with the first generation transcatheter aortic valve interventional (TAVI) devices now commercially available in Europe.

The patients in the study also benefited from a significant improvement in quality of life as measured by NYHA functional class. Most patients had an improvement of at least two functional classes. “The improvement in functional class appears to be due to the low incidence of perivalvular leak, and the unique ability of the Direct Flow device to seal to the native annulus,” said Dr. Hendrik Treede, a cardiothoracic surgeon and study coinvestigator in Hamburg.

Also at the TCT meeting, professor Schofer reported two-year data on the first patient treated with the Direct Flow Medical 22 Fr. Percutaneous Aortic Valve (PAV) System. Before treatment, the 81-year-old patient was suffering from critical aortic stenosis with an effective orifice area of 0.56 cm2 and was NYHA Class III. Because of severe comorbidities, the patient was not a surgical candidate. At the two year follow-up the excellent acute clinical result was maintained; the patient remains NYHA Class I with a mean pressure gradient of 10 mmHg, an effective orifice area of 1.98 cm2 and he maintains an active life style. An additional six patients implanted with the Direct Flow Medical device are surviving beyond 18 months post treatment despite having an average age of 82 and a logistic EuroScore of greater than 27 at implant.

“We are pleased to report the positive data, results and clinical outcomes demonstrated in our patients at one-year post implant and beyond, particularly in the areas of stable post procedure gradients and improved NYHA functional class,” said professor Schofer. “We anticipate that with the development of the new 18 Fr. device from Direct Flow Medical we will be able to accelerate patient enrollment and increase our clinical experience with this unique, next generation device.”

For more information:

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Overlay Init